Elicio Therapeutics Inc (ELTX) Stock Price, Quote & News

Company Profile

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma...

Industry: Biotechnology

Sector: Healthcare

Phone: (857) 209-0050

Website: elicio.com

Address:

451 D Street, 5th Floor Suite 501, Boston, United States

Woooehoo Oct. 22 at 11:03 AM

$ELTX I see it as unlikely this doesn’t go decently higher or decently lower with data in q4

3 · Reply

DrevanTheStillblade Oct. 19 at 8:33 PM

Don’t sleep on VRME while many tech names trade on hype, this one trades on value + technical setup. Golden cross brewing on the daily, 10‑day action above $1 reflecting compliance improvement, and it’s still under the radar. This combination rarely stays hidden for long. $PSNY $ELTX $XELA $SLNO

0 · Reply

justiceforb_85 Oct. 12 at 2:22 AM

$ELTX we've received a possible hint that DFS wil be outstanding in the P2. Median mKRAS-specific T cell response ~44 when prior studies showed clinical efficacy around 9.17. I am very hopeful this translates into clinically meaningful outcomes. https://elicio.com/press_releases/elicio-therapeutics-reports-eli-002-7p-achieved-robust-mkras-specific-t-cell-responses-in-99-of-evaluable-patients-in-ongoing-phase-2-amplify-7p-trial/

0 · Reply

COYIinnewyork Oct. 9 at 6:43 PM

$ELTX I've only been holding a few thousand shares. I'm holding it amongst others, but I've always wondered with this in particular why MRK, BMY, or PFE don't swoop it up to fill their immuno-oncology pipelines. Do you think they are waiting on the specific data like everyone else? Would ELTX sell to one of them on positive data or would partnering be the way to go?

1 · Reply

outlawinvestor1 Oct. 3 at 4:38 PM

$ERAS #KRAS landscape. SA doesn't update mc/ev in real-time - ERAS mc is now ~$720 million, cash is ~$350 million. @Night_Owl_Biotech $RVMD $VSTM $ELTX $ARVN

0 · Reply

justiceforb_85 Sep. 29 at 7:12 PM

$ELTX this is excellent news and means more patients would potentially qualify for ELI-002 7P. https://elicio.com/press_releases/elicio-therapeutics-announces-investigator-initiated-phase-1-trial-to-be-conducted-by-memorial-sloan-kettering-cancer-center-and-funded-by-the-lustgarten-foundation-for-neoadjuvant-eli-002-7p-in-pancr/

0 · Reply

LawrenceLay406 Sep. 21 at 10:52 AM

$ELTX Biotech with novel approach. Pre-revenue volatility. Chart shows high risk/reward. Avoid.

0 · Reply

Woooehoo Sep. 18 at 12:17 PM

$ELTX if p2 is anything like p1 should show solid efficacy of T cell response is even better

2 · Reply

justiceforb_85 Sep. 17 at 4:59 PM

$ELTX looking forward to P2 data later this year. Wonder if they would qualify for accelerated approval pending P3 completion.

1 · Reply

PMMstocks Sep. 17 at 1:52 PM

$ELTX https://elicio.com/press_releases/elicio-therapeutics-reports-eli-002-7p-achieved-robust-mkras-specific-t-cell-responses-in-99-of-evaluable-patients-in-ongoing-phase-2-amplify-7p-trial/

0 · Reply

Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

Sep 18, 2025, 8:00 AM EDT - 5 weeks ago

Elicio Therapeutics Reports Inducement Grants

Sep 17, 2025, 8:00 AM EDT - 5 weeks ago

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

Aug 12, 2025, 8:00 AM EDT - 2 months ago

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients

Aug 7, 2025, 4:30 PM EDT - 2 months ago

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 7:00 AM EDT - 2 months ago

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

Jun 17, 2025, 8:00 AM EDT - 4 months ago

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer

Jun 4, 2025, 8:00 AM EDT - 5 months ago

Elicio Therapeutics Secures $10 Million in Financing

May 13, 2025, 4:05 PM EDT - 5 months ago

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Apr 16, 2025, 4:05 PM EDT - 6 months ago

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

Mar 31, 2025, 7:00 AM EDT - 7 months ago

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Mar 24, 2025, 7:00 AM EDT - 7 months ago

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

Jan 31, 2025, 12:22 PM EST - 9 months ago

Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data

Jan 22, 2025, 7:30 AM EST - 9 months ago

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

Dec 12, 2024, 7:00 AM EST - 11 months ago

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Nov 13, 2024, 4:05 PM EST - 1 year ago

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 7, 2024, 4:05 PM EST - 1 year ago

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Sep 13, 2024, 8:30 AM EDT - 1 year ago

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 4:30 PM EDT - 1 year ago

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Elicio Therapeutics Announces Proposed Public Offering

Jun 27, 2024, 4:01 PM EDT - 1 year ago

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P

May 23, 2024, 5:30 PM EDT - 1 year ago

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

May 15, 2024, 4:30 PM EDT - 1 year ago

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

Apr 5, 2024, 4:30 PM EDT - 1 year ago

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Mar 29, 2024, 8:30 AM EDT - 1 year ago

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

Mar 18, 2024, 8:00 AM EDT - 1 year ago

Elicio Therapeutics Announces $6.0 Million Private Placement Financing

Mar 6, 2024, 8:30 AM EST - 1 year ago

Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

Feb 5, 2024, 8:30 AM EST - 1 year ago

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 25, 2024, 9:00 AM EST - 1 year ago

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Jan 17, 2024, 8:30 AM EST - 1 year ago

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

Jan 16, 2024, 8:30 AM EST - 1 year ago

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

Jan 11, 2024, 8:30 AM EST - 1 year ago

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

Jan 9, 2024, 6:00 AM EST - 1 year ago

Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic's AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002

Dec 22, 2023, 9:00 AM EST - 2 years ago

Elicio Therapeutics Announces $7.0 Million Private Placement Financing

Dec 4, 2023, 8:00 AM EST - 2 years ago

Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 9, 2023, 4:30 PM EST - 2 years ago

Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Nov 3, 2023, 4:30 PM EDT - 2 years ago

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC 2023) Annual Meeting

Sep 27, 2023, 5:30 PM EDT - 2 years ago

Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer

Sep 7, 2023, 8:00 AM EDT - 2 years ago

Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer

Aug 28, 2023, 8:00 AM EDT - 2 years ago

Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics

Aug 11, 2023, 8:30 AM EDT - 2 years ago

Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Aug 9, 2023, 8:00 AM EDT - 2 years ago

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model

Jun 6, 2023, 8:00 AM EDT - 2 years ago

Elicio Therapeutics Completes Reverse Merger and Provides a Corporate Update

Jun 3, 2023, 9:00 AM EDT - 2 years ago

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting

Woooehoo Oct. 22 at 11:03 AM

$ELTX I see it as unlikely this doesn’t go decently higher or decently lower with data in q4

3 · Reply

DrevanTheStillblade Oct. 19 at 8:33 PM

0 · Reply

justiceforb_85 Oct. 12 at 2:22 AM

0 · Reply

COYIinnewyork Oct. 9 at 6:43 PM

1 · Reply

outlawinvestor1 Oct. 3 at 4:38 PM

$ERAS #KRAS landscape. SA doesn't update mc/ev in real-time - ERAS mc is now ~$720 million, cash is ~$350 million. @Night_Owl_Biotech $RVMD $VSTM $ELTX $ARVN

0 · Reply

justiceforb_85 Sep. 29 at 7:12 PM

0 · Reply

LawrenceLay406 Sep. 21 at 10:52 AM

$ELTX Biotech with novel approach. Pre-revenue volatility. Chart shows high risk/reward. Avoid.

0 · Reply

Woooehoo Sep. 18 at 12:17 PM

$ELTX if p2 is anything like p1 should show solid efficacy of T cell response is even better

2 · Reply

justiceforb_85 Sep. 17 at 4:59 PM

$ELTX looking forward to P2 data later this year. Wonder if they would qualify for accelerated approval pending P3 completion.

1 · Reply

PMMstocks Sep. 17 at 1:52 PM

$ELTX https://elicio.com/press_releases/elicio-therapeutics-reports-eli-002-7p-achieved-robust-mkras-specific-t-cell-responses-in-99-of-evaluable-patients-in-ongoing-phase-2-amplify-7p-trial/

0 · Reply

topstockalerts Sep. 17 at 1:31 PM

$ELTX keep an eye for today..

0 · Reply

humdime Sep. 17 at 1:09 PM

$ELTX Not just replicating Phase 1 but actually improving it. We’ll see the real efficacy, but comparing this data with Phase 1, it looks like a game changer at bargain price

0 · Reply

truehealthvalue Sep. 17 at 12:55 PM

$ELTX may I be wrong, but today news are best-in-class results. Better than MRNA with 100x lower valuation

0 · Reply

outlawinvestor1 Sep. 15 at 1:51 PM

$RNXT just the beginning for renovo and a few others in pancan. $RVMD $VSTM $ELTX $CADL

0 · Reply

NVDAMillionaire Sep. 5 at 10:22 PM

$ELTX Brilliant piece that captures ELTX's situation perfectly. So if you want to update your understanding of ELTX or get to know ELTX better, this is essential reading. https://beyondspx.com/quote/ELTX/elicio-therapeutics-amp-technology-s-promise-meets-a-critical-funding-juncture-nasdaq-eltx#analysis

1 · Reply

Pokerguden Aug. 26 at 1:56 PM

$ELTX Seems like next catalysts are a few months away. 10-20% drop from here before next spike. Hoping for sub 9 entry 1 month from now.

0 · Reply

justiceforb_85 Aug. 25 at 6:14 PM

$ELTX added more. Look forward to data in Q4.

0 · Reply

GannAnalysisCapital Aug. 23 at 1:22 PM

$ELTX Elicio Therapeutics Inc is a clinical stage oncology company with vaccine platform

0 · Reply

justiceforb_85 Aug. 19 at 7:25 PM

$ELTX holding strong. Impressed there hasn't been an offering (though wouldn't blame the company if they did).

4 · Reply

Woooehoo Aug. 19 at 12:39 PM

$ELTX needs one big randomized DFS win in Q4 and then there is no reason this isn’t at least a $B market cap

0 · Reply

RealtorNewYork Aug. 19 at 12:26 AM

$ELTX The study was sponsored and funded by Elicio Therapeutics, the Massachusetts company that developed the vaccine. Mutations in the KRAS gene are responsible for half of colorectal cancers and more than 90% of pancreatic cancers. The vaccine, which targets those mutations, was given via a series of injections to activate an immune response in the lymph nodes. A majority (21 out of 25) of the patients generated "KRAS-specific T cells," which indicates a stronger immune response. The ones with higher T-cell responses showed a longer relapse-free survival compared to those with lower responses, the researchers found. For three colorectal cancer patients and three pancreatic cancer patients, the vaccine appeared to remove all disease biomarkers.

0 · Reply

RealtorNewYork Aug. 19 at 12:19 AM

$ELTX BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of follow-up data from the Phase 1 AMPLIFY-201 study evaluating ELI-002 in the peer-reviewed scientific journal, Nature Medicine. The article, entitled, “Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: Phase 1 AMPLIFY-201 trial final results,” highlights that with extended follow-up, more than two-thirds of participants (17 of 25) whose T cell responses exceeded the antitumor efficacy threshold experienced a significantly reduced risk for relapse or death.

0 · Reply

Market Cap	158.48M
Revenue (ttm)	0.00
Net Income (ttm)	-51.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	5.10

Volume	81,000
Avg Vol	107,262
Day's Range	N/A - N/A
Shares Out	16.34M
Stochastic %K	34%
Beta	1.19
Analysts	Strong Sell
Price Target	$15.50